Phase III trial finds 32% lower chance of disease recurrence, progression, or death with immunotherapy plus chemotherapy versus chemotherapy alone Peer-Reviewed Publication UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER JOHN HEYMACH M.D., PH.D. CREDIT: THE UNIVERSITY OF MD ANDERSON CANCER CENTER HOUSTON ― A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy...
